sorry my mistake, I just read p1 of the ASX noticeBiotech cos need to realise that results without corresponding action arent that interesting... Personally if I was a Roche or similar I would do a T/O of cos like BNO while they are still cheap
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint